剑桥大学+超越人类健康的生命科学：英国现代工业生物技术-112页_3mb

Life Sciences Beyond Human Health: Modern Industrial Biotechnology in the UK

Key Findings from March 2023 Report:

• Definition and Scope: Modern industrial biotechnology (MIB) is defined as the application of biological systems for economic and eco-friendly processes outside human health. It includes areas like agriculture, food, and environmental biotechnology.

• UK MIB Landscape: The UK has around 202 MIB firms, with strong R&D but challenges in commercialization. Key sub-sectors include agriculture (22%) and veterinary sciences (18%). Turnover is £4.7 billion, with SMEs dominating.

• Strengths and Opportunities: The UK is globally competitive in research and development. Opportunities arise in sustainability, agribiotech, and consumer products. McKinsey estimates biotech's non-health impact will reach over $2 trillion by 2030-40.

• Challenges: Limited scale-up facilities, lack of patient capital for later-stage funding, and reliance on international manufacturing. Value capture is challenging due to lower margins in certain industries.

• Regulation and Innovation: Regulation balances risk management and innovation; lessons from AI and GMO debates. Scientific advances like gene editing and digitalization drive growth.

• Sectoral Futures: Potential growth in agribiotech, commercial genomics, animal health, and underpinning technologies. Policy recommendations focus on IP strategies, funding mechanisms, and enhancing clusters.

International Context: UK ranks fifth in biotech publications but faces competition from the US and China in business strength. Policy interventions, including tax incentives and funding programs, can support MIB development.